RxDoctor Payments Data

Xequiel Hernandez, MD

Family Medicine · New York, NYNPI 1164783254

Payments from drug & device makers

$659in general payments, 2019–2025

Across 30 payments — averaging $21.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$120
  • AbbVie$107
  • Novo Nordisk$86
  • Viiv Healthcare Company$57
  • Gilead$53
  • Exact Sciences$40
  • plus $196 from 10 others

What the payments were for

  • Food & beverage$659100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$659 in reported general payments places this provider in the 60th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$8,295
Medicare patients
33
Services billed
78

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala48$181,385
JulucaDolutegravir/Rilpivirine20$64,831
MounjaroTirzepatide48$49,929
JardianceEmpagliflozin46$46,489
TrulicityDulaglutide26$40,058
OzempicSemaglutide27$38,368
DovatoDolutegravir Sodium/Lamivudine13$36,183
PrezcobixDarunavir/Cobicistat13$30,340
LinzessLinaclotide42$28,734
EliquisApixaban27$17,406
EntrestoSacubitril/Valsartan19$12,214
VerquvoVericiguat12$7,560
BrilintaTicagrelor13$6,300
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$5,586
LumiganBimatoprost11$3,997

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$53$181,38548 claims
Viiv Healthcare CompanyJuluca, Dovato$57$101,01433 claims
Lilly USA, LLCMounjaro, Trulicity$12$89,98774 claims
Novo NordiskOzempic$86$38,36827 claims
AbbVieLinzess, Lumigan$107$32,73153 claims
PfizerEliquis$120$17,40627 claims
NovartisEntresto$16$12,21419 claims
MerckVerquvo$23$7,56012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,321 family medicine providers in New York.

Other family medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →